394 related articles for article (PubMed ID: 28844471)
1. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation.
Valle A; Barbagiovanni G; Jofra T; Stabilini A; Perol L; Baeyens A; Anand S; Cagnard N; Gagliani N; Piaggio E; Battaglia M
J Immunol; 2015 Mar; 194(5):2117-27. PubMed ID: 25646305
[TBL] [Abstract][Full Text] [Related]
3. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
[TBL] [Abstract][Full Text] [Related]
4. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.
Ablamunits V; Bisikirska B; Herold KC
Eur J Immunol; 2010 Oct; 40(10):2891-901. PubMed ID: 21038470
[TBL] [Abstract][Full Text] [Related]
6. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
Tooley JE; Vudattu N; Choi J; Cotsapas C; Devine L; Raddassi K; Ehlers MR; McNamara JG; Harris KM; Kanaparthi S; Phippard D; Herold KC
Eur J Immunol; 2016 Jan; 46(1):230-41. PubMed ID: 26518356
[TBL] [Abstract][Full Text] [Related]
7. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice.
Serr I; Fürst RW; Achenbach P; Scherm MG; Gökmen F; Haupt F; Sedlmeier EM; Knopff A; Shultz L; Willis RA; Ziegler AG; Daniel C
Nat Commun; 2016 Mar; 7():10991. PubMed ID: 26975663
[TBL] [Abstract][Full Text] [Related]
8. Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.
Diggins KE; Serti E; Muir V; Rosasco M; Lu T; Balmas E; Nepom G; Long SA; Linsley PS
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351781
[TBL] [Abstract][Full Text] [Related]
9. Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease.
Åkesson K; Tompa A; Rydén A; Faresjö M
Clin Exp Immunol; 2015 Apr; 180(1):70-82. PubMed ID: 25421756
[TBL] [Abstract][Full Text] [Related]
10. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8
Hutten TJA; Norde WJ; Woestenenk R; Wang RC; Maas F; Kester M; Falkenburg JHF; Berglund S; Luznik L; Jansen JH; Schaap N; Dolstra H; Hobo W
Biol Blood Marrow Transplant; 2018 Apr; 24(4):666-677. PubMed ID: 29197680
[TBL] [Abstract][Full Text] [Related]
11. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
Waldron-Lynch F; Henegariu O; Deng S; Preston-Hurlburt P; Tooley J; Flavell R; Herold KC
Sci Transl Med; 2012 Jan; 4(118):118ra12. PubMed ID: 22277969
[TBL] [Abstract][Full Text] [Related]
12. CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients.
Makwana N; Foley B; Fernandez S; Lee S; Irish A; Pircher H; Price P
Eur J Immunol; 2017 Aug; 47(8):1324-1334. PubMed ID: 28586095
[TBL] [Abstract][Full Text] [Related]
13. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
Ding L; Gysemans CA; Stangé G; Heremans Y; Yuchi Y; Takiishi T; Korf H; Chintinne M; Carr RD; Heimberg H; Pipeleers D; Mathieu C
PLoS One; 2014; 9(9):e107935. PubMed ID: 25268801
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG; Koenig S; Chatenoud L; Herold KC
Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection.
Torrado E; Fountain JJ; Liao M; Tighe M; Reiley WW; Lai RP; Meintjes G; Pearl JE; Chen X; Zak DE; Thompson EG; Aderem A; Ghilardi N; Solache A; McKinstry KK; Strutt TM; Wilkinson RJ; Swain SL; Cooper AM
J Exp Med; 2015 Aug; 212(9):1449-63. PubMed ID: 26282876
[TBL] [Abstract][Full Text] [Related]
16. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
17. Decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients.
Mohammadnia-Afrouzi M; Zavaran Hosseini A; Khalili A; Abediankenari S; Hosseini V; Maleki I
Autoimmunity; 2015; 48(8):556-61. PubMed ID: 26333292
[TBL] [Abstract][Full Text] [Related]
18. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
Shameli A; Yamanouchi J; Tsai S; Yang Y; Clemente-Casares X; Moore A; Serra P; Santamaria P
Eur J Immunol; 2013 Feb; 43(2):394-403. PubMed ID: 23180662
[TBL] [Abstract][Full Text] [Related]
19. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
20. Expression of KLRG1 and CD127 defines distinct CD8
Wu H; Tang X; Kim HJ; Jalali S; Pritchett JC; Villasboas JC; Novak AJ; Yang ZZ; Ansell SM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
